Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Lifeline Biotechnologies' Classification of Breast Cancer is No Longer a Myth but a Fact
April 11th, 2007
Lifeline Biotechnologies, Inc. (OTCPK: LBTN) announced that its Neural Network Classification of breast cancer with blind temperature screening is no longer a myth but a fact. According to Louis Keith, MD, PhD, Lifeline Biotechnologies, Medical Director and Vice President, "Predicting the future with Artificial Intelligence has always been a hit or miss proposition. Predictions have been made on computers whose functional capacities were limited but ever increasing. This means, in practical terms, that yesterday's predictions, however good, became out of date with the next generation of computers." Jim Holmes, Lifeline's CEO, stated, "After almost...
Source: Medical Patent Law Weekly (2007-04-11)
|
